Hims and Hers Health Inc vs ThredUp Inc — how do they compare? Hims and Hers Health Inc trades at $30.88 (market cap $6.55B), while ThredUp Inc trades at $2.47 (market cap $308.63M). The key difference: Hims and Hers Health Inc is far larger — about 21.2× ThredUp Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and ThredUp Inc for 29 Days on average.
| HIMS | TDUP | |
|---|---|---|
Market Cap | $6.55B | $308.63M |
Volume | 14,842,814 | 3,024,364 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $9.41 |
52-Week Low | $14.52 | $2.12 |
Typical Hold Time | 21 Days | 29 Days |
Enterprise Value | $7.25B | $306.81M |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
ThredUp (TDUP) trades at $2.455, up 10.59% in the past 24 hours, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed earnings expectations with a net loss. Fundamentals show a high gross margin of 79.52% but negative net income margin and ROE, while cash flow from operations improved to $10.65 million in 2025.
The outlook is mixed: analyst consensus is 57% buy with no sell ratings, but profitability remains a challenge amid promotional headwinds. Risks include ongoing losses, competitive pressures, and a recent stock decline following guidance cuts. Investment opportunity hinges on execution toward profitability despite current bearish technicals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →